市場調査レポート

商品コード

1344398

僧帽弁疾患治療薬市場：薬剤クラス別、年齢層別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Mitral Valve Disease Therapeutics Market By Drug class, By Age group, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2023年05月30日
発行: Allied Market Research
ページ情報: 英文 268 Pages
納期: 2～3営業日

価格

PDF (Business License)

USD 5,730 842,252円

レポートPDFを1名がご利用いただけるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は5回まで可能です。 2名以上でご利用の場合、追加料金を支払う事によりユーザーを最大５名まで追加する事が可能です。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,411,104円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.99円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Allied Market Researchが発行した最新レポート「僧帽弁疾患治療薬市場」によると、僧帽弁疾患治療薬市場は2022年に6億774万米ドルと評価され、2023年から2032年にかけてCAGR 2.8%で成長し、2032年には8億340万米ドルに達すると予測されています。

Mitral Valve Disease Therapeutics Market-IMG1

僧帽弁疾患治療薬市場の成長を促す主な要因は、僧帽弁疾患の有病率の増加です。僧帽弁閉鎖不全症、僧帽弁逸脱症、僧帽弁狭窄症などの僧帽弁疾患と診断される患者数が増加しています。例えば、Journal of Clinical Medicine 2022によると、僧帽弁閉鎖不全症は欧州で2番目に多く、米国では最も多い心臓弁膜症であり、75歳以上の人口における有病率は9.3％です。したがって、僧帽弁疾患の有病率の増加は治療薬に対する需要をもたらし、市場の成長を促進します。

さらに、僧帽弁疾患は、リウマチ熱や先天性心疾患などの様々な要因によって引き起こされる可能性があります。リウマチ熱は、溶連菌感染後に発症する炎症性疾患で、炎症が心臓に広がり、僧帽弁を含む心臓弁に損傷を与える可能性があります。そのため、この損傷が僧帽弁膜症につながり、息切れ、疲労、胸痛、動悸などの症状を引き起こすことがあります。また、先天性心疾患は、生まれつき存在する構造上の異常です。一部の先天性心疾患は僧帽弁の機能に影響を及ぼし、僧帽弁膜症を引き起こすことがあります。そのため、僧帽弁膜症の症状を管理するために、β遮断薬、利尿薬、カルシウム拮抗薬などの治療薬が処方され、市場の成長を促進しています。

さらに、僧帽弁置換術の増加や治療薬の採用が市場の成長を促進すると予想されています。例えば、抗凝固剤は僧帽弁疾患を管理し、脳卒中などの重篤な合併症を引き起こす可能性のある血栓を予防するために一般的に使用されています。そのため、抗凝固剤の採用が増加し、市場成長の原動力となっています。

さらに、僧帽弁疾患の発生率の上昇は、人口の高齢化や高血圧、糖尿病、肥満などの危険因子の増加など、いくつかの要因に起因しています。人口の高齢化に伴い、僧帽弁疾患を発症するリスクは増加します。これは弁が時間の経過とともに傷ついたり弱くなったりすることで、誤作動を起こしやすくなるためです。さらに、高血圧や肥満などの危険因子の増加も僧帽弁疾患の発症リスクを高めます。さらに、患者やヘルスケア専門家の間で僧帽弁疾患に対する認識が高まり、早期診断・早期治療につながっており、医療介入の需要を促進しています。世界中の政府が僧帽弁疾患の新しい治療法の研究開発に投資しており、それが新しい治療法の開発につながっています。

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - 僧帽弁疾患の有病率の増加
  - 僧帽弁疾患の症状を管理するための医薬品の採用の増加
  - 老年人口の増加
- 抑制要因
  - 代替治療法の利用可能性
- 機会
  - 新興市場における成長機会
COVID-19による市場への影響分析

第4章僧帽弁疾患治療薬市場：薬剤クラス別

β遮断薬
利尿薬
抗凝固薬
その他

第5章僧帽弁疾患治療薬市場：年齢層別

55歳未満
55歳以上

第6章僧帽弁疾患治療薬市場：流通チャネル別

病院薬局
ドラッグストアおよび小売薬局
オンラインプロバイダー

第7章僧帽弁疾患治療薬市場：地域別

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他アジア太平洋地域
ラテンアメリカ・中東・アフリカ
- ブラジル
- サウジアラビア
- 南アフリカ
- その他の地域

第8章競合情勢

イントロダクション
主要成功戦略
主要10企業の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第9章企業プロファイル

Zydus Lifesciences Limited
Pfizer Inc.
Bayer AG
Novartis AG
Viatris Inc.
Alembic Ltd
Sun Pharmaceutical Industries Limited
Cipla Ltd
Teva Pharmaceutical Industries Ltd.
Sanofi

図表

LIST OF TABLES

TABLE 01. GLOBAL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 02. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR BETA BLOCKERS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR DIURETICS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR ANTICOAGULANTS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 07. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR BELOW 55 YEARS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR ABOVE 55 YEARS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 10. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 11. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 12. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 18. U.S. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 19. U.S. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 20. U.S. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 21. CANADA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 22. CANADA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 23. CANADA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 24. MEXICO MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 25. MEXICO MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 26. MEXICO MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 27. EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 28. EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 29. EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 30. EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 31. GERMANY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 32. GERMANY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 33. GERMANY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. FRANCE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 35. FRANCE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 36. FRANCE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 37. UK MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 38. UK MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 39. UK MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 40. ITALY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 41. ITALY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 42. ITALY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 43. SPAIN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 44. SPAIN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 45. SPAIN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 53. JAPAN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 54. JAPAN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 55. JAPAN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 56. CHINA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 57. CHINA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 58. CHINA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 59. INDIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 60. INDIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 61. INDIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 71. LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 72. LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 73. LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 74. LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 75. BRAZIL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 76. BRAZIL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 77. BRAZIL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 81. SOUTH AFRICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 84. REST OF LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 87. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
TABLE 88. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
TABLE 89. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
TABLE 90. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
TABLE 91. PFIZER INC.: KEY EXECUTIVES
TABLE 92. PFIZER INC.: COMPANY SNAPSHOT
TABLE 93. PFIZER INC.: PRODUCT SEGMENTS
TABLE 94. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 95. BAYER AG: KEY EXECUTIVES
TABLE 96. BAYER AG: COMPANY SNAPSHOT
TABLE 97. BAYER AG: PRODUCT SEGMENTS
TABLE 98. BAYER AG: PRODUCT PORTFOLIO
TABLE 99. NOVARTIS AG: KEY EXECUTIVES
TABLE 100. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 101. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 102. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 103. VIATRIS INC.: KEY EXECUTIVES
TABLE 104. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 105. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 106. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 107. ALEMBIC LTD: KEY EXECUTIVES
TABLE 108. ALEMBIC LTD: COMPANY SNAPSHOT
TABLE 109. ALEMBIC LTD: PRODUCT SEGMENTS
TABLE 110. ALEMBIC LTD: PRODUCT PORTFOLIO
TABLE 111. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 114. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 115. CIPLA LTD: KEY EXECUTIVES
TABLE 116. CIPLA LTD: COMPANY SNAPSHOT
TABLE 117. CIPLA LTD: PRODUCT SEGMENTS
TABLE 118. CIPLA LTD: PRODUCT PORTFOLIO
TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 123. SANOFI: KEY EXECUTIVES
TABLE 124. SANOFI: COMPANY SNAPSHOT
TABLE 125. SANOFI: PRODUCT SEGMENTS
TABLE 126. SANOFI: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN MITRAL VALVE DISEASE THERAPEUTICS MARKET (2023-2032)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALMITRAL VALVE DISEASE THERAPEUTICS MARKET
FIGURE 10. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR BETA BLOCKERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR DIURETICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR ANTICOAGULANTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR BELOW 55 YEARS, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR ABOVE 55 YEARS, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. MITRAL VALVE DISEASE THERAPEUTICS MARKET BY REGION, 2022
FIGURE 23. U.S. MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 24. CANADA MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 25. MEXICO MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 26. GERMANY MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 27. FRANCE MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 28. UK MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 29. ITALY MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 30. SPAIN MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 31. REST OF EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 32. JAPAN MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 33. CHINA MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 34. INDIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 35. AUSTRALIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 36. SOUTH KOREA MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 37. REST OF ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 38. BRAZIL MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 39. SAUDI ARABIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 40. SOUTH AFRICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 41. REST OF LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 46. COMPETITIVE DASHBOARD
FIGURE 47. COMPETITIVE HEATMAP: MITRAL VALVE DISEASE THERAPEUTICS MARKET
FIGURE 48. TOP PLAYER POSITIONING, 2022
FIGURE 49. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 50. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 51. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 52. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 53. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 54. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 55. BAYER AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 56. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 57. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 58. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 59. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 60. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 61. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 62. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 63. ALEMBIC LTD: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 64. ALEMBIC LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 65. ALEMBIC LTD: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 66. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 67. SUN PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 68. CIPLA LTD: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 69. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 70. CIPLA LTD: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 71. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 72. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 73. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)
FIGURE 74. SANOFI S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 75. SANOFI S.A.: REVENUE SHARE BY REGION, 2022 (%)

Product Code: A74639

According to a new report published by Allied Market Research, titled, "Mitral Valve Disease Therapeutics Market," The mitral valve disease therapeutics market was valued at $607.74 million in 2022, and is estimated to reach $803.4 million by 2032, growing at a CAGR of 2.8% from 2023 to 2032.

The major factor driving the growth of the mitral valve disease therapeutics market is increase in prevalence of mitral valve conditions. There has been an increase in the number of patients diagnosed with mitral valve diseases such as mitral regurgitation, mitral prolapse, and mitral stenosis. For instance, Journal of Clinical Medicine 2022, stated that, mitral regurgitation is the second most common valvular heart disease in Europe and the most common in the U.S., with a prevalence of 9.3% in the population aged over 75 years. Thus, rise in prevalence of mitral valve conditions results in demand for therapeutics and propels the market growth.

Further, mitral valve disease can be caused by various factors, such as rheumatic fever and congenital heart defects. Rheumatic fever is an inflammatory disease that can occur after a streptococcal infection, leading to inflammation that can spread to the heart, causing damage to the heart valves, including the mitral valve. Thus, this damage can lead to mitral valve disease, which can cause symptoms such as shortness of breath, fatigue, chest pain, and heart palpitations. In addition, congenital heart defects are structural abnormalities that are present at birth. Some congenital heart defects can affect the function of the mitral valve, leading to mitral valve disease. Thus, to manage the symptoms of mitral valve disease, therapeutics such as beta blockers, diuretics, and calcium channel blockers are prescribed, thereby driving the growth of the market.

Furthermore, rise in mitral valve replacement procedures and adoption of therapeutics is expected to propel the market growth. For instance, anticoagulants are commonly used to manage mitral valve disease and prevent blood clots, which can lead to serious complications such as stroke. Thus, rise in adoption of anticoagulants drives the market growth.

Further, rise in the incidence of mitral valve diseases can be attributed to several factors, such as aging population and increase in risk factors such as high blood pressure, diabetes, and obesity. As the population ages, the risk of developing mitral valve disease increases. This is because the valve can become damaged or weakened over time, making it more prone to malfunction. In addition, the rise in risk factors such as high blood pressure and obesity can increase the risk of developing mitral valve disease. Moreover, rise in awareness of mitral valve diseases among patients and healthcare professionals has led to earlier diagnosis and treatment, driving demand for medical interventions. Governments around the world are investing in research and development of new treatments for mitral valve disease, which has led to the development of novel therapeutics.

In addition, increased awareness about the symptoms and risk factors associated with mitral valve disease has led to more people seeking medical treatment for the condition, which has further driven the growth of the market. However, availability of other treatment options for mitral valve disease is expected to restrain the growth of mitral valve disease therapeutics market. There are several alternative treatment options available for mitral valve disease, such as surgical interventions and transcatheter procedures. These alternative options may be preferred by some patients or may be recommended by healthcare providers based on individual patient needs, thus restraining the growth of market.

The global mitral valve disease therapeutics market is segmented into drug class, age group, distribution channel, and region. On the basis of drug class, the market is categorized into beta blockers, diuretics, anticoagulants, and others. As per age group, the market is categorized into below 55 years and above 55 years. According to distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global mitral valve disease therapeutics market are Zydus Lifesciences Limited, Pfizer Inc., Bayer AG, Novartis AG, Viatris Inc., Alembic Ltd., Teva Pharmaceutical Industries Ltd., Cipla Ltd., Sun Pharmaceutical Industries Limited, and Sanofi.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mitral valve disease therapeutics market analysis from 2022 to 2032 to identify the prevailing mitral valve disease therapeutics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the mitral valve disease therapeutics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global mitral valve disease therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Distribution channel

Hospital pharmacies
Drug store and retail pharmacies
Online providers

By Drug class

Beta blockers
Diuretics
Anticoagulants
Others

By Age group

Below 55 years
Above 55 years

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Bayer AG
Novartis AG
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Viatris Inc.
Sun Pharmaceutical Industries Limited
Cipla Ltd
Zydus Lifesciences Limited
Sanofi
Alembic Ltd

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increasing prevalence of mitral valve diseases
  - 3.4.1.2. Rise in adoption of pharmaceutical drugs to manage mitral valve disease symptoms
  - 3.4.1.3. Rise in geriatric population

3.4.2. Restraints
- 3.4.2.1. Availability of alternative treatment options

3.4.3. Opportunities
- 3.4.3.1. Growth opportunities in emerging markets

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Beta blockers
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Diuretics
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Anticoagulants
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Others
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country

CHAPTER 5: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Below 55 years
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Above 55 years
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drug store and retail pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Drug class
- 7.2.3. Market size and forecast, by Age group
- 7.2.4. Market size and forecast, by Distribution channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Drug class
  - 7.2.5.1.3. Market size and forecast, by Age group
  - 7.2.5.1.4. Market size and forecast, by Distribution channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Drug class
  - 7.2.5.2.3. Market size and forecast, by Age group
  - 7.2.5.2.4. Market size and forecast, by Distribution channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Drug class
  - 7.2.5.3.3. Market size and forecast, by Age group
  - 7.2.5.3.4. Market size and forecast, by Distribution channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Drug class
- 7.3.3. Market size and forecast, by Age group
- 7.3.4. Market size and forecast, by Distribution channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Drug class
  - 7.3.5.1.3. Market size and forecast, by Age group
  - 7.3.5.1.4. Market size and forecast, by Distribution channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Drug class
  - 7.3.5.2.3. Market size and forecast, by Age group
  - 7.3.5.2.4. Market size and forecast, by Distribution channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Drug class
  - 7.3.5.3.3. Market size and forecast, by Age group
  - 7.3.5.3.4. Market size and forecast, by Distribution channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Drug class
  - 7.3.5.4.3. Market size and forecast, by Age group
  - 7.3.5.4.4. Market size and forecast, by Distribution channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Drug class
  - 7.3.5.5.3. Market size and forecast, by Age group
  - 7.3.5.5.4. Market size and forecast, by Distribution channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Drug class
  - 7.3.5.6.3. Market size and forecast, by Age group
  - 7.3.5.6.4. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Drug class
- 7.4.3. Market size and forecast, by Age group
- 7.4.4. Market size and forecast, by Distribution channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Drug class
  - 7.4.5.1.3. Market size and forecast, by Age group
  - 7.4.5.1.4. Market size and forecast, by Distribution channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Drug class
  - 7.4.5.2.3. Market size and forecast, by Age group
  - 7.4.5.2.4. Market size and forecast, by Distribution channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Drug class
  - 7.4.5.3.3. Market size and forecast, by Age group
  - 7.4.5.3.4. Market size and forecast, by Distribution channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Drug class
  - 7.4.5.4.3. Market size and forecast, by Age group
  - 7.4.5.4.4. Market size and forecast, by Distribution channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Drug class
  - 7.4.5.5.3. Market size and forecast, by Age group
  - 7.4.5.5.4. Market size and forecast, by Distribution channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Drug class
  - 7.4.5.6.3. Market size and forecast, by Age group
  - 7.4.5.6.4. Market size and forecast, by Distribution channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Drug class
- 7.5.3. Market size and forecast, by Age group
- 7.5.4. Market size and forecast, by Distribution channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Drug class
  - 7.5.5.1.3. Market size and forecast, by Age group
  - 7.5.5.1.4. Market size and forecast, by Distribution channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Drug class
  - 7.5.5.2.3. Market size and forecast, by Age group
  - 7.5.5.2.4. Market size and forecast, by Distribution channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Drug class
  - 7.5.5.3.3. Market size and forecast, by Age group
  - 7.5.5.3.4. Market size and forecast, by Distribution channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Drug class
  - 7.5.5.4.3. Market size and forecast, by Age group
  - 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Zydus Lifesciences Limited
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
9.2. Pfizer Inc.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Bayer AG
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. Novartis AG
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
9.5. Viatris Inc.
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. Alembic Ltd
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. Sun Pharmaceutical Industries Limited
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Cipla Ltd
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. Teva Pharmaceutical Industries Ltd.
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Sanofi
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance

僧帽弁疾患治療薬市場：薬剤クラス別、年齢層別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Mitral Valve Disease Therapeutics Market By Drug class, By Age group, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章僧帽弁疾患治療薬市場：薬剤クラス別

第5章僧帽弁疾患治療薬市場：年齢層別

第6章僧帽弁疾患治療薬市場：流通チャネル別

第7章僧帽弁疾患治療薬市場：地域別

第8章競合情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Distribution channel

By Drug class

By Age group

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS

CHAPTER 5: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP

CHAPTER 6: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

僧帽弁疾患治療薬市場：薬剤クラス別、年齢層別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Mitral Valve Disease Therapeutics Market By Drug class, By Age group, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 僧帽弁疾患治療薬市場：薬剤クラス別

第5章 僧帽弁疾患治療薬市場：年齢層別

第6章 僧帽弁疾患治療薬市場：流通チャネル別

第7章 僧帽弁疾患治療薬市場：地域別

第8章 競合情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Distribution channel

By Drug class

By Age group

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS

CHAPTER 5: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP

CHAPTER 6: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章僧帽弁疾患治療薬市場：薬剤クラス別

第5章僧帽弁疾患治療薬市場：年齢層別

第6章僧帽弁疾患治療薬市場：流通チャネル別

第7章僧帽弁疾患治療薬市場：地域別

第8章競合情勢

第9章企業プロファイル